• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抑肽酶——治疗呼吸系统疾病的药物。

Aprotinin-Drug against Respiratory Diseases.

机构信息

ChemDiv Inc., San Diego, CA 92130, USA.

ASAVI LLC, 1835 East Hallandale Blvd #442, Hallandale Beach, FL 33009, USA.

出版信息

Int J Mol Sci. 2023 Jul 6;24(13):11173. doi: 10.3390/ijms241311173.

DOI:10.3390/ijms241311173
PMID:37446350
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10342444/
Abstract

Aprotinin (APR) was discovered in 1930. APR is an effective pan-protease inhibitor, a typical "magic shotgun". Until 2007, APR was widely used as an antithrombotic and anti-inflammatory drug in cardiac and noncardiac surgeries for reduction of bleeding and thus limiting the need for blood transfusion. The ability of APR to inhibit proteolytic activation of some viruses leads to its use as an antiviral drug for the prevention and treatment of acute respiratory virus infections. However, due to incompetent interpretation of several clinical trials followed by incredible controversy in the literature, the usage of APR was nearly stopped for a decade worldwide. In 2015-2020, after re-analysis of these clinical trials' data the restrictions in APR usage were lifted worldwide. This review discusses antiviral mechanisms of APR action and summarizes current knowledge and prospective regarding the use of APR treatment for diseases caused by RNA-containing viruses, including influenza and SARS-CoV-2 viruses, or as a part of combination antiviral treatment.

摘要

抑肽酶（APR）于 1930 年被发现。APR 是一种有效的广谱蛋白酶抑制剂，是一种典型的“万能枪”。直到 2007 年，APR 被广泛用作心脏和非心脏手术中的抗血栓和抗炎药物，以减少出血，从而减少输血的需求。APR 抑制某些病毒的蛋白水解激活的能力使其可用作抗病毒药物，用于预防和治疗急性呼吸道病毒感染。然而，由于对几项临床试验的解释不当，随后文献中出现了令人难以置信的争议，APR 的使用在全球范围内几乎停止了十年。在 2015-2020 年，对这些临床试验数据进行重新分析后，全球范围内解除了 APR 使用的限制。本文讨论了 APR 作用的抗病毒机制，并总结了目前关于 APR 治疗含 RNA 病毒引起的疾病（包括流感和 SARS-CoV-2 病毒）的知识和前景，或作为联合抗病毒治疗的一部分。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/91a97ea9dac9/ijms-24-11173-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/6c820b3314d4/ijms-24-11173-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/bc8dc4fa3a13/ijms-24-11173-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/40b0b92d70a4/ijms-24-11173-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/0c50687df793/ijms-24-11173-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/106ce4e2a6bf/ijms-24-11173-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/87761f08359e/ijms-24-11173-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/baac65ca3bb2/ijms-24-11173-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/91a97ea9dac9/ijms-24-11173-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/6c820b3314d4/ijms-24-11173-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/bc8dc4fa3a13/ijms-24-11173-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/40b0b92d70a4/ijms-24-11173-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/0c50687df793/ijms-24-11173-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/106ce4e2a6bf/ijms-24-11173-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/87761f08359e/ijms-24-11173-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/baac65ca3bb2/ijms-24-11173-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a414/10342444/91a97ea9dac9/ijms-24-11173-g008.jpg

相似文献

1
Aprotinin-Drug against Respiratory Diseases.抑肽酶——治疗呼吸系统疾病的药物。
Int J Mol Sci. 2023 Jul 6;24(13):11173. doi: 10.3390/ijms241311173.
2
Aprotinin Inhibits SARS-CoV-2 Replication.抑肽酶抑制 SARS-CoV-2 复制。
Cells. 2020 Oct 30;9(11):2377. doi: 10.3390/cells9112377.
3
Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.抑肽酶治疗 SARS-CoV-2：一项评估泛蛋白酶抑制剂治疗中度 COVID-19 的安全性和有效性的随机 III 期研究。
Eur J Clin Invest. 2022 Jun;52(6):e13776. doi: 10.1111/eci.13776. Epub 2022 Apr 5.
4
Aprotinin (II): Inhalational Administration for the Treatment of COVID-19 and Other Viral Conditions.抑肽酶（II）：用于治疗 COVID-19 和其他病毒病的吸入式给药。
Int J Mol Sci. 2024 Jun 29;25(13):7209. doi: 10.3390/ijms25137209.
5
The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2.抑肽酶联合选定抗病毒药物对流感肺炎和由 SARS-CoV-2 引起的冠状病毒感染的小鼠模型的疗效。
Molecules. 2022 Aug 5;27(15):4975. doi: 10.3390/molecules27154975.
6
Effect of Aprotinin and Avifavir Combination Therapy for Moderate COVID-19 Patients.阿替普酶和阿维福韦联合治疗中度 COVID-19 患者的效果。
Viruses. 2021 Jun 27;13(7):1253. doi: 10.3390/v13071253.
7
[Aprotinin-induced inhibition of pandemic influenza virus A(H1N1) reproduction].抑肽酶诱导对甲型H1N1大流行性流感病毒复制的抑制作用
Vopr Virusol. 2011 May-Jun;56(3):24-8.
8
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.瑞德西韦、洛匹那韦/利托那韦和氯喹/羟氯喹影响新型 SARS-CoV-2 的抗病毒机制研究进展。
Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24.
9
Aprotinin (I): Understanding the Role of Host Proteases in COVID-19 and the Importance of Pharmacologically Regulating Their Function.抑肽酶（I）：了解宿主蛋白酶在 COVID-19 中的作用及药理调节其功能的重要性。
Int J Mol Sci. 2024 Jul 10;25(14):7553. doi: 10.3390/ijms25147553.
10
Inhibitory effects of aprotinin on influenza A and B viruses in vitro and in vivo.抑肽酶对甲型和乙型流感病毒的体外和体内抑制作用。
Sci Rep. 2021 May 3;11(1):9427. doi: 10.1038/s41598-021-88886-1.

引用本文的文献

1
Functional characterization of a common XIa inhibitory Kunitz-domain Shp4 from nine schistosoma secreted proteins with diverse C-terminal fragments.来自九种具有不同C端片段的血吸虫分泌蛋白的常见XIa抑制性Kunitz结构域Shp4的功能表征。
PLoS Negl Trop Dis. 2025 Jul 8;19(7):e0013282. doi: 10.1371/journal.pntd.0013282. eCollection 2025 Jul.
2
Colistin enhances caspofungin antifungal efficacy against Aspergillus fumigatus by modulating calcium homeostasis and stress responses.黏菌素通过调节钙稳态和应激反应增强棘白菌素对烟曲霉的抗真菌疗效。
Nat Commun. 2025 Jul 1;16(1):5967. doi: 10.1038/s41467-025-60991-z.
3
Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses.

本文引用的文献

1
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.Molnupiravir 治疗非住院成人 COVID-19 的 2/3 期试验。
NEJM Evid. 2022 Feb;1(2):EVIDoa2100043. doi: 10.1056/EVIDoa2100043. Epub 2021 Dec 16.
2
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.莫努匹拉韦或安慰剂用于新冠肺炎住院患者的随机试验
NEJM Evid. 2022 Feb;1(2):EVIDoa2100044. doi: 10.1056/EVIDoa2100044. Epub 2021 Dec 16.
3
Highly Pathogenic Avian Influenza A(H5N1) Virus Outbreak in New England Seals, United States.
潜在的广谱抗病毒药物：对抗新出现和再次出现的呼吸道RNA病毒的关键武器库。
Int J Mol Sci. 2025 Feb 10;26(4):1481. doi: 10.3390/ijms26041481.
4
Development and Prospects of Furin Inhibitors for Therapeutic Applications.furin 抑制剂治疗应用的开发与前景。
Int J Mol Sci. 2024 Aug 24;25(17):9199. doi: 10.3390/ijms25179199.
5
Aprotinin (II): Inhalational Administration for the Treatment of COVID-19 and Other Viral Conditions.抑肽酶（II）：用于治疗 COVID-19 和其他病毒病的吸入式给药。
Int J Mol Sci. 2024 Jun 29;25(13):7209. doi: 10.3390/ijms25137209.
6
The relationship between autophagy and respiratory viruses.自噬与呼吸病毒的关系。
Arch Microbiol. 2024 Mar 4;206(4):136. doi: 10.1007/s00203-024-03838-3.
美国新英格兰海豹中爆发高致病性禽流感（H5N1）。
Emerg Infect Dis. 2023 Apr;29(4):786-791. doi: 10.3201/eid2904.221538.
4
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective.抗靶标，抗 SARS-CoV-2 先导物，药物，以及药物发现遗传学联盟的视角。
J Med Chem. 2023 Mar 23;66(6):3664-3702. doi: 10.1021/acs.jmedchem.2c01229. Epub 2023 Mar 1.
5
Short-Term Effectiveness of Oral Nirmatrelvir/Ritonavir Against the SARS-CoV-2 Omicron Variant and Culture-Positive Viral Shedding.口服奈玛特韦/利托那韦对 SARS-CoV-2 奥密克戎变异株的短期疗效及培养阳性病毒脱落情况
J Korean Med Sci. 2023 Feb 27;38(8):e59. doi: 10.3346/jkms.2023.38.e59.
6
Preparing for the Next Influenza Season: Monitoring the Emergence and Spread of Antiviral Resistance.为下一个流感季节做准备：监测抗病毒药物耐药性的出现与传播。
Infect Drug Resist. 2023 Feb 15;16:949-959. doi: 10.2147/IDR.S389263. eCollection 2023.
7
SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming.SARS-CoV-2 在气道上皮细胞中的复制需要纤毛的运动和微绒毛的重编程。
Cell. 2023 Jan 5;186(1):112-130.e20. doi: 10.1016/j.cell.2022.11.030. Epub 2022 Dec 2.
8
Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques.联合使用莫努匹韦-奈玛特韦能提高对食蟹猴体内 SARS-CoV-2 的抑制效果。
JCI Insight. 2023 Feb 22;8(4):e166485. doi: 10.1172/jci.insight.166485.
9
Influenza antivirals and their role in pandemic preparedness.流感抗病毒药物及其在大流行准备中的作用。
Antiviral Res. 2023 Feb;210:105499. doi: 10.1016/j.antiviral.2022.105499. Epub 2022 Dec 23.
10
A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19.一项评估甲磺酸达比加群酯（DWJ1248）治疗成人轻度至中度 COVID-19 患者的有效性和安全性的双盲、随机、安慰剂对照、II 期临床研究。
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0045222. doi: 10.1128/aac.00452-22. Epub 2022 Dec 14.